The Female Health Company's Second Generation Product, FC2, is Issued Patent for...

The Female Health Company's Second Generation Product, FC2, is Issued Patent for
Europe

CHICAGO, Nov. 12, 2009 (GLOBE NEWSWIRE) -- The Female Health Company
(Nasdaq:FHCO), today reported that a patent has been issued on its second
generation product, FC2, by the European patent office. In addition to Europe,
FC2 patents have been issued in Canada, Australia, the Republic of South Africa
and the People's Republic of China. FC2 patent applications are pending in the
U.S., Japan and various other countries.

The Company recently announced completion of its 150% expansion of FC2
manufacturing capacity at its Malaysia facility. All outstanding orders for FC1
have been fulfilled. Current and future orders will be fulfilled with FC2 from
the Malaysia facility.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets
the FC2 Female Condom(R) (FC2), which is available in about 100 countries around
the world. The Company owns certain worldwide rights to the FC2 Female
Condom(R), including patents that have been issued in Europe, Canada, Australia,
South Africa and the People's Republic of China and are pending in various other
countries. The FC2 Female Condom(R) is the only available FDA-approved product
controlled by a woman that offers dual protection against sexually transmitted
diseases, including HIV/AIDS, and unintended pregnancy. The World Health
Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

For more information about the Female Health Company visit the Company's website
at http://www.femalehealth.com and http://www.fc2femalecondom.com. If you would
like to be added to the Company's e-mail alert list, please send an e-mail to
FHCInvestor@femalehealthcompany.com .

"Safe Harbor" statement under the Private Securities Litigation Reform Action of
1995:

The statements in this release which are not historical facts are
forward-looking statements based upon the Company's current plans and
strategies, and reflect the Company's current assessment of the risks and
uncertainties related to its business, including such things as product demand
and market acceptance; the economic and business environment and the impact of
government pressures; currency risks; capacity; efficiency and supply
constraints; and other risks detailed in the Company's press releases,
shareholder communications and Securities and Exchange Commission filings.
Actual events affecting the Company and the impact of such events on the
Company's operations may vary from those currently anticipated.

-0-
CONTACT: The Female Health Company
William R. Gargiulo, Jr.
231.526.1244
Donna Felch
312.595.9123